Nanosystems as Drug Delivery Carrier: From Nature to the Medication

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 14273

Special Issue Editor

Special Issue Information

Dear Colleagues

In the field of research into nanomedicine, the synthesis of devices of molecular size by using various types of natural polymer like cyclodextrins has been intensively studied from a pharmacological point of view. Thus, research intp the scope of drug delivery systems has been focused on the transport of useful substances and active drugs, which, because of their insolubility in the bloodstream, limit the possibilities of medical treatment in the organism. From the formation of inclusion complexes to the formation of nanoparticles linked to natural or synthetic polymers, suprqamolecular systems have been successful because of their versatility at transporting small substances; their isolation; and their elimination of toxins, heavy elements, and molecules that, due to their physical-chemical characteristics, are difficult to handle in an aqueous environment.

Therefore, the possibility to receive research articles/reviews about the contribution of several drug delivery systems from natural or synthetic sources could help us to understand the importance of choosing nanocapsules, liposomes, or multiples structures to carry drugs under chemical effects in living systems.

Prof. Dr. Eduardo Sobarzo-Sánchez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery systems,
  • cyclodextrin,
  • nanomedicine,
  • active drugs,
  • bioavailability

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

24 pages, 3791 KiB  
Article
Topical Delivery of Meloxicam using Liposome and Microemulsion Formulation Approaches
by Julia Zhang, Anna Froelich and Bozena Michniak-Kohn
Pharmaceutics 2020, 12(3), 282; https://doi.org/10.3390/pharmaceutics12030282 - 21 Mar 2020
Cited by 37 | Viewed by 6243
Abstract
The aim of this study is to develop, characterize and compare conventional liposome, deformable liposome (transfersome) and microemulsion formulations as potential topical delivery systems for meloxicam. Liposomes were characterized in terms of vesicle size, zeta potential and entrapment efficiency. For microemulsions, particle size, [...] Read more.
The aim of this study is to develop, characterize and compare conventional liposome, deformable liposome (transfersome) and microemulsion formulations as potential topical delivery systems for meloxicam. Liposomes were characterized in terms of vesicle size, zeta potential and entrapment efficiency. For microemulsions, particle size, electrical conductivity and viscosity studies were performed to assess the structure of the investigated systems. An ex vivo skin permeation study has been conducted to compare these formulations. The dermal and transdermal delivery of meloxicam using these formulations can be a promising alternative to conventional oral delivery of non-steroidal anti-inflammatory drugs (NSAIDs) with enhanced local and systemic onset of action and reduced side effects. Full article
(This article belongs to the Special Issue Nanosystems as Drug Delivery Carrier: From Nature to the Medication)
Show Figures

Graphical abstract

Review

Jump to: Research

13 pages, 463 KiB  
Review
Nanopharmaceutics: Part I—Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU
by Eliana B. Souto, Gabriela F. Silva, João Dias-Ferreira, Aleksandra Zielinska, Fátima Ventura, Alessandra Durazzo, Massimo Lucarini, Ettore Novellino and Antonello Santini
Pharmaceutics 2020, 12(2), 146; https://doi.org/10.3390/pharmaceutics12020146 - 11 Feb 2020
Cited by 76 | Viewed by 6786
Abstract
The latest advances in pharmaceutical technology are leading to the development of cutting edged approaches to produce what is now known as the “Holy Grail” of medicine—nanopharmaceutics. Over the latest decade, the pharmaceutical industry has made important contributions to the scale up of [...] Read more.
The latest advances in pharmaceutical technology are leading to the development of cutting edged approaches to produce what is now known as the “Holy Grail” of medicine—nanopharmaceutics. Over the latest decade, the pharmaceutical industry has made important contributions to the scale up of these new products. To ensure their quality, efficacy, and safety for human use, clinical trials are mandatory. Yet, regulation regarding nanopharmaceuticals is still limited with a set of guidelines being recently released with respect to compliance with quality and safety. For the coming years, updates on regulatory issues about nanopharmaceuticals and their use in clinical settings are expected. The use of nanopharmaceuticals in clinical trials depends on the approval of the production methods and assurance of the quality of the final product by implementation and verification of the good manufacturing practices (GMP). This review addresses the available legislation on nanopharmaceuticals within the European Union (EU), the GMP that should be followed for their production, and the current challenges encountered in clinical trials of these new formulations. The singular properties of nanopharmaceuticals over their bulk counterparts are associated with their size, matrix composition, and surface properties. To understand their relevance, four main clinical trial guidelines, namely, for intravenous iron-based nanopharmaceuticals, liposomal-based nanopharmaceuticals, block copolymer micelle-based nanopharmaceuticals, and related to surface coating requirements, are described here. Full article
(This article belongs to the Special Issue Nanosystems as Drug Delivery Carrier: From Nature to the Medication)
Show Figures

Graphical abstract

Back to TopTop